Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC) Meeting Abstract

  

Authors:	Cortes, J.; Crown, J.; Awada, A.; Schmid, P.; Gianni, L.; Garcia-Estevez, L.; Martinez-Janez, N.; Chan, S.; Steinberg, J. L.; Blaney, M.; Tudor, I. C.; Uppal, H.; Peterson, A.; Miller, K.; Yardley, D. A.; Hudis, C. A.; Traina, T. A.
Abstract Title:	Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC)
Meeting Title:	18th European Cancer Conference (ECCO 18)
Journal Title:	European Journal of Cancer
Volume:	51
Issue:	Suppl. 3
Meeting Dates:	2015 Sep 25-29
Meeting Location:	Vienna, Austria
ISSN:	0959-8049
Publisher:	Elsevier Inc.
Date Published:	2015-09-01
Start Page:	S265
Language:	English
ACCESSION:	WOS:000361887401173
PROVIDER:	wos
DOI:	10.1016/S0959-8049(16)30756-0
Notes:	Meeting Abstract: 1802 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/82685